Study on Capecitabine Combined For Advanced Liver Cancer

Objective To evaluate the clinical efficacy of capecitabine combined with chemoembolization(TACE) for advanced liver cancer.Methods Forty patients with liver cancer were retrospectively divided into two groups:Treatment group,on the basis of TACE,20 patients received oral capecitabine at 2000 mg/m2,twice-daily for 14 days followed by 7-day rest period and repeated in every three week intervals for more than two cycles.Control group,20 patients received TACE only at 1-month intervals for at least two cycles.Results In capecitabine and TACE group:there were 0 CR,13 PR,6 SD and 1 PD;the overall response rate was 65.0%;the AFP and tumor reduction rates were 60.0% and 70.0%;the median survival time was 11.5 months.In the TACE only group:there were 0 CR,12 PR,16 SD and 12 PD;the overall response rate was 30.0 %;the AFP and tumor reduction rates were 32.4% and 32.4 %;the median survival time was 7.6months.Comparison of complications:the incidence of hand-foot syndrome of the treatment group and the control group was 55.0% and 10.0% respectively,the incidence of bone barrow suppression of the treatment group and the control group was 25.0% and 22.5% respectively,the incidence of diarrhea of the treatment group and the control group was 15.0% and 12.5% respectively,the incidence of liver toxicity of the treatment group and the control group was 90.0% and 82.5% respectively,Most of these toxicities were tolerable at grade 1~2.Conclusion Capecitabine combined with TACE may be safe and effective for advanced liver cancer and superior to single TACE.